| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 982.7 | 1,004.9 |
| Net income | 333.1 | 54.4 |
| EPS (diluted, $ a share) | $6.86 | $1.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +512.0% |
|---|---|
| Revenue, year on year | -2.2% |
| Operating margin | 20.6% |
10-Q filed with the SEC, NYSE: CRL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Charles River Laboratories International, Inc.: key numbers
- Share price
- $332.16Close, Nov 17
- Market cap
- $15.9B
- Shares outstanding
- 47.92MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Charles River Laboratories International, Inc.
All →Charles River Laboratories International Signs $470M M&A Deal with Frontage Holdings Corporation
Charles River Laboratories has entered into definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for $470 million in cash. The deal includes up to $75 million in additional contingent payments and is intended to expand Charles River's clinical bioanalysis capabilities to support clients across the full drug development lifecycle. The transaction is expected to close in the first half of 2027.
- Value
- $470M
- Counterparty
- Frontage Holdings Corporation
Charles River Laboratories International Financial Results
Charles River Laboratories reported Q3 2026 revenue of $982.7 million and organic revenue growth of 4.7%, marking its second consecutive quarter of organic growth. The company increased its full-year 2026 guidance for both revenue and non-GAAP earnings per share, driven by outperformance in its Discovery and Safety Assessment (DSA) segment.
- Term
- Q3 2026
“Our third-quarter results were highlighted by a return to organic revenue growth for the second consecutive quarter and significant margin expansion, which drove non-GAAP earnings per share growth of 27%. We were pleased with the performance of our DSA and Manufacturing segments, which both delivered organic revenue growth and improved profitability.”
James C. Foster, Chairman, President and Chief Executive Officer
Charles River Laboratories International Insider James C. Foster Sells $8.41M of Stock
James C. Foster sold 24,042 shares of Charles River Laboratories International, Inc. at $350.00 a share, worth $8.41M in total on Oct 22, 2026. Shares held after the trade: 31,596 (-43.2%).
- Value
- $8.41M
- Shares
- 24,042
- Price
- $350.00
- Holding change
- -43.2%
- Trade date
- Oct 22, 2026
Charles River Laboratories International CEVP, Disc & Safety Assessment Shannon M. Parisotto Sells $743K of Stock
Shannon M. Parisotto, CEVP, Disc & Safety Assessment, sold 2,156 shares of Charles River Laboratories International, Inc. at $344.41 a share, worth $743K in total on Oct 21, 2026. Shares held after the trade: 4,807 (-31.0%).
- Value
- $743K
- Shares
- 2,156
- Price
- $344.41
- Role
- CEVP, Disc & Safety Assessment
- Holding change
- -31.0%
- Trade date
- Oct 21, 2026
Charles River Laboratories International CEVP, Disc & Safety Assessment Shannon M. Parisotto Sells $303K of Stock
Shannon M. Parisotto, CEVP, Disc & Safety Assessment, sold 981 shares of Charles River Laboratories International, Inc. at $308.44 a share, worth $303K in total on Oct 5, 2026. Shares held after the trade: 4,807 (-16.9%).
- Value
- $303K
- Shares
- 981
- Price
- $308.44
- Role
- CEVP, Disc & Safety Assessment
- Holding change
- -16.9%
- Trade date
- Oct 5, 2026
Charles River Laboratories International Investor Presentation
Charles River Laboratories is hosting its 2026 Investor Day to unveil its 'Pathway to Purpose' strategic vision, which aims to modernize operations and generate over $300 million in cumulative savings through 2030. The company reaffirmed its 2026 guidance at the upper end of prior ranges and introduced long-term targets including a 5-7% organic revenue CAGR and a ~24% non-GAAP operating margin by 2030.
- Term
- through 2030